Novo Nordisk A/S
Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries.
Key staff involved in EBiSC
Mattias Hansson (Director) – is heading the department of Stem Cell Biology at Novo Nordisk A/S. His research is focussed on the development of cell replacement therapy for the treatment of diabetes mellitus with particular interest in translational stem cell research. Mattias has obtained his research training in stem cell biology as a Marie Curie fellow at the Hagedorn Research Institute. He holds a Ph.D. from the Faculty of Health Sciences at the University of Copenhagen and a M.Sc. in chemical engineering from Lund University, Sweden.
More information: www.novonordisk.com »